ESR1 and triple-negative breast carcinoma: The expression of estrogen receptors (ER), progesterone receptors (PR), and human epidermal growth factor receptor 2 (HER-2) determines the variability in subtypes of BCa, including luminal A/B, HER-2 overexpression and triple-negative breast cancer (TNBC) (5).